GSK
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$52.43
장중 · Vol 105.7K · 52주 $38.63–$61.70 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $50.53 · Aug 31, 2026
GSK 가격 추세
종가
$50.53
시가
$50.22
고가
$50.81
저가
$50.49
30초 브리핑
GSK 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 60%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 10.1배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.0배
거래량은 최근 평균 범위입니다.
2026-10-28
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
GSK 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
79 New Oxford Street · London, United Kingdom · 직원 66,841명
시가총액
$100.64B
Trailing P/E
15.9
최근 12개월 이익 기준
Forward P/E
10.1
이익 증가 기대 반영
EPS (TTM)
$3.20
배당 수익률
3.58%
배당성향
56.8%
베타
0.29
시장보다 방어적
ROE
33.4%
P/B
4.21
EV/EBITDA
10.8
52주 범위
$38.63 – $61.70
현재 위치 60%
거래량
2.23M
20일 평균 2.33M · 1.0배
애널리스트 의견
매수 25%
총 8명 · 0m
DITM LEAPS Analysis
GSK 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GSK280121C00033000 | 1/21/28 · 1.4Y | $33.00 | $18.30 | 2.5x | 0.9081 | 5.7% | 5.46% | 36.85% | 25 | 89.00 | |
| GSK280121C00035000 | 1/21/28 · 1.4Y | $35.00 | $16.65 | 2.7x | 0.8898 | 8.4% | 5.41% | 35.40% | 237 | 88.65 | |
| GSK280121C00038000 | 1/21/28 · 1.4Y | $38.00 | $14.25 | 3.0x | 0.8553 | 14.0% | 6.32% | 33.72% | 90 | 82.06 | |
| GSK280121C00040000 | 1/21/28 · 1.4Y | $40.00 | $12.80 | 3.3x | 0.8277 | 19.9% | 6.25% | 32.80% | 92 | 77.13 | |
| GSK280121C00042000 | 1/21/28 · 1.4Y | $42.00 | $10.40 | 3.9x | 0.7986 | 20.7% | 25.00% | 31.54% | 266 | 70.55 |
재무제표
GSK 연간 손익·현금흐름·재무상태
매출 성장률
+4.1%
최근 연간 YoY
EPS 성장률
+123.2%
최근 연간 YoY
영업이익률
25.5%
최근 연간
FCF 마진
14.6%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $32.67B+4.1% | $31.38B+3.5% | $30.33B+3.4% | $29.32B |
| 매출총이익 | $23.65B+5.9% | $22.33B+2.6% | $21.76B+10.1% | $19.77B |
| 영업이익 | $8.34B+50.5% | $5.54B-24.5% | $7.34B+9.2% | $6.73B |
| 순이익 | $5.72B+122.0% | $2.58B-47.7% | $4.93B-67.1% | $14.96B |
| 희석 EPS | $2.78+123.2% | $1.24-48.1% | $2.40-67.3% | $7.32 |
| EBITDA | $10.40B+56.0% | $6.67B-26.6% | $9.08B+5.6% | $8.60B |
| 영업현금흐름 | $7.74B+18.1% | $6.55B-3.2% | $6.77B-8.6% | $7.40B |
| 잉여현금흐름 | $4.76B+33.1% | $3.57B-19.3% | $4.42B-14.0% | $5.14B |
| 총자산 | $61.12B+2.8% | $59.46B+0.8% | $59.01B-1.9% | $60.15B |
| 총부채 | $17.72B+4.3% | $16.99B-5.7% | $18.02B-14.1% | $20.99B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
GSK 실적·배당 일정
매출 하단
$8.74B
EPS 하단
$1.32
매출 상단
$9.02B
배당 지급일
2026-10-08
D-37
실적 발표일
2026-10-28
D-57
EPS 상단
$1.37
매출 컨센서스
$8.90B
EPS 컨센서스
$1.34
배당락일
2026-08-14
18일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 14, 2026 | $0.4520 |
| May 15, 2026 | $0.4610 |
| Feb 20, 2026 | $0.4860 |
| Nov 14, 2025 | $0.4170 |
| Aug 15, 2025 | $0.4280 |
| May 16, 2025 | $0.4290 |
| Feb 21, 2025 | $0.4010 |
| Nov 15, 2024 | $0.3890 |
뉴스
GSK 관련 최신 기사
- 일반
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday
MT Newswires · Aug 27, 2026
규제·법률GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer
GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
Zacks · Aug 24, 2026
- 제품·기술
Exchange-Traded Funds, Equity Futures Fall Pre-Bell Monday as Investors Await Details on US Sanctions Against Iran
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr
MT Newswires · Aug 24, 2026
실적GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth
GSK PLC (LSE:GSK, NYSE:GSK) got a grudging nod from Citi on Thursday, as the investment bank lifted its earnings forecasts for the drugmaker but stopped well short of a buy call. The shares edged up 0.31% to 1,922p as Citi kept its 'neutral' rating, tweaking its model after GSK's...
Proactive · Aug 20, 2026
제품·기술Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Zacks · Aug 18, 2026
- 일반
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
European equities traded in the US as American depositary receipts started the week tracking modestl
MT Newswires · Aug 17, 2026
실적Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?
On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm’s total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to £2.80 billion and Core EPS rose 9% CER […]
Insider Monkey · Aug 13, 2026
제품·기술Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.
24/7 Wall St. · Aug 13, 2026
- 제품·기술
Trump Plans to Sign Order on Splitting Up Combined Measles Shot
(Bloomberg) -- President Donald Trump is expected to sign an executive order Monday that would recommend breaking up the combined measles, mumps and rubella vaccine into three separate shots, according to a person familiar with the matter. Most Read from BloombergChina Unleashes $28 Trillion Capital Markets to Challenge US in AIStocks Wobble on Hormuz Standoff as Nvidia Sinks: Markets WrapIran Shakes Up Security Team After Saying Oman Deal ‘Very Close’Trump Amps Up Pressure on Billionaire Sargea
Bloomberg · Aug 10, 2026
- 실적
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.
Zacks · Aug 5, 2026
홀더
GSK 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
17.5%
기관 보유 (유동주식)
17.5%
내부자 보유
0.1%
기관 수
1,208
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| FMR, LLC | 64.96M | $3.26B | 3.2% | -4.0% | Jun 30, 2026 |
| Dodge & Cox Inc. | 48.20M | $2.42B | 2.4% | -17.8% | Jun 30, 2026 |
| Fisher Asset Management, LLC | 35.72M | $1.80B | 1.8% | 3.5% | Jun 30, 2026 |
| Primecap Management Company | 25.18M | $1.27B | 1.2% | -0.1% | Jun 30, 2026 |
| Wellington Management Group, LLP | 11.40M | $572.66M | 0.6% | -2.7% | Jun 30, 2026 |
| JTC Employer Solutions Trustee Ltd. | 8.59M | $431.80M | 0.4% | -5.0% | Jun 30, 2026 |
| Morgan Stanley | 7.66M | $384.79M | 0.4% | -30.6% | Jun 30, 2026 |
| Royal Bank of Canada | 7.59M | $381.34M | 0.4% | 1.1% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 6.92M | $347.91M | 0.3% | -5.5% | Jun 30, 2026 |
| Acadian Asset Management. LLC | 6.66M | $334.69M | 0.3% | -43.5% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.
